Deloitte.

Healthcare and Life Sciences Predictions 2020

A bold future?

David Hearn, Head of Deloitte Consulting 17 April 2015



What we know today and estimate about tomorrow

Our industry is changing quickly









- 2. 2015 Global Life Sciences Sector Outlook, Deloitte DTTL, 2014
- 3. Informa Plc Market Line Extracted 181014

Health consumers

2020

- Better informed
- Genetic profile
- Social media
- Expectations
- Prevention

3



Electronic health records

Today

Smartphone App

Genome

Video

Healthcare delivery systems

2020

- Home & community
- Technology
- Virtual
- Hospital reserved
- Robotic
- 3D printing



- Electronic Healthcare Records
- "Patients know best"
- Retail outlets
 - Al & 3D examples

Wearables and mHealth

2020

- Wearables
- Comprehensive view
- Widespread
- New partnerships
- Self management& prevention



- **Venture funding**
- mHealth market
- Over 100,000 health Aps

Big Data

2020

A national infrastructure priority

Personalised treatment

Improving outcomes and

productivity



- Supply of data from EMR, mhealth
- **Big Data technologies**
- Genetic counselling and testing


Regulatory compliance and patient safety

2020

Regulatory agencies adapt

Data driven


 Encourage innovation



Research and Development

2020

- The networked laboratory
- Partnerships
- Distributed
- Disease biology and genetics
- Cost of care



- Two thirds of drugs launched were partnerships
- New models of R&D

Pharmaceutical commercial model

2020

Shift from volume to value

Sales reps are medical educators

Multi Channel Marketing

Outcome based



Today

Sales reps restricted

US rep numbers down8% (2011-12)

J&J Innovation centre

The pharmaceutical enterprise

2020

Single, global organisation

Global business services

Real time, integrated data

Mobile, technology enabled

workers



- **GBS Adoption**
- Virtual HR solutions
- Cloud

Corporate reputation

2020

Repairing negative corporate

reputation

Inclusive

Transparent



- Patient survey: 2013
- Ethical marketing 26%
- Integrity 25%

www.deloitte.com

This is an internal document which provides confidential advice and guidance to partners and staff of Deloitte LLP and its subsidiaries. It is not to be copied or made available to any other party.